Search

everythinglearnresearchcommunity

for

Search:↓

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

The conversation is about the effectiveness of finasteride, oral minoxidil, and RU58841 for hair loss treatment. Opinions vary on improvement after 7 months of treatment, and there are concerns about the safety of using non-approved chemicals like RU58841.

The user is using caffeine shampoo with baicapil, microneedling, massage, and procapil lotion for hair loss. Replies suggest the user is balding and recommend finasteride.

The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

After six months on Dutasteride, the user's hair is worse than before, despite previously trying finasteride and RU/Fluridil without success. Some suggest continuing Dutasteride and adding progress photos, while others share their positive experiences or advise sticking to one treatment for at least a year.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

A user is experimenting with applying undiluted peppermint oil to their scalp daily to stimulate hair growth, based on a rat study where peppermint oil outperformed minoxidil. The user reports immediate hair thickening and increased scalp blood flow, while others in the conversation express skepticism, humor, and concern about the undiluted application.

The user has been on Finasteride and oral Minoxidil for hair loss and experienced minimal side effects. They suggest that a healthy lifestyle, including good sleep, exercise, diet, skincare, and mental health care, may help reduce the perceived side effects of Finasteride, although another user disagrees, emphasizing that side effects can vary and may not be mitigated by lifestyle alone.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

People discussed their intense hair loss treatments, including the use of dutasteride, RU58841, minoxidil, tretinoin, essential oils, microneedling, and various topical sprays. Some users reported success with these methods in preventing hair loss and stimulating hair growth.

The conversation is about hair loss and the specific treatments mentioned are finasteride and minoxidil.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

User tried Propecia and topical finasteride but experienced side effects. Switched to Dutasteride and oral Minoxidil, then added CosmeRNA for hair loss treatment.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.

How combining minoxidil, finasteride and pyrilutamide has helped the user with hair loss. The user also acknowledges that it takes time to see any results and that minoxidil is necessary for stimulating new hair growth.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.